Targeting the Homologous Recombination Pathway in Cancer With a Novel Class of RAD51 Inhibitors

Targeting the Homologous Recombination Pathway in Cancer With a Novel Class of RAD51 Inhibitors

Targeting DNA damage response (DDR) pathway has been proposed as an approach for amplifying tumor-specific replicative lesions. RAD51 plays a central role in the DDR process, and thus represents a promising anti-tumor target. We here report the discovery of a series of next generation RAD51 inhibito...

Full description

Bibliographic Details
Main Authors: Peng Gu, Liting Xue, Chunyan Zhao, Wenjing Li, Zhen Jiang, Aiguo Liu, Tingting Li, Lu Liu, Markus Decker, Xiaoxuan Cheng, Wenqing Yang, Renhong Tang
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-05-01
Series:Frontiers in Oncology
Subjects:
Keywords: RAD51
small molecule inhibitor
DNA damage response
homologous recombination
synthetic lethality
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.885186/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.885186/full

Similar Items